African Treatment Issues and Late Diagnosis
Issues for African sub-groups
Pre-Meeting for Gilead
Community meeting update from Gilead, Q & A
CROI Feedback
Issues for African sub-groups
Pre-Meeting for Gilead
Community meeting update from Gilead, Q & A
CROI Feedback
Confidence building workshop
Skill-building session
NHS structures in the UK
Getting other advocates involved
What next – active involvement
UKCHIC Proposed Ageing Study
Ageing with HIV: Project Overview Will we ever get to be old and wise?
BHIVA Conference overview
Pre-meeting for Abbott
Community Meeting update from Abbott
Community Q & A with Abbott
HIV and Ageing interactive session
BHIVA Routine Monitoring Guidelines
HIV Treatment Advocacy Overview
Definitions of Advocacy
Denver Principles
History of Advocacy Film highlights
Advocacy Training in Practice
Pre-Meeting for Bristol-Myers Squibb
Bristol-Myers Squibb Community Meeting, Q&A
Company meeting: BMS
IAS Conference Feedback
BHIVA Routine Monitoring Guidelines
HIV Treatment Advocacy Overview
Definitions of Advocacy
Denver Principles
History of Advocacy Film highlights
Advocacy Training in Practice
Pre-Meeting for Bristol-Myers Squibb
Bristol-Myers Squibb Community Meeting, Q&A
Company meeting: BMS
IAS Conference Feedback
Introducing the HIV Vaccine Advisory
Board-Ken Legg, MRC and St Marys Hospital
Resistance Explored
Professor Deenan Pillay
Company meeting: GSK abacavir, pipeline drugs and merger
BMS/Gilead patient education programme
Training and presentations: Immunology
Company meeting:Tibotec
Etravirine overview including comment on drug interaction,
Darunavir European license extended to all treatment-experienced
Rilpivirine (TMC-278) Next generation first-line NNRTI
and pipeline HIV plus HCV and TB
Training and presentations: Mexico Feedback. BHIVA Education Scientific Committee Feedback. BHIVHA/CHIVHA Feedback. Update on the HCQ and PIVOT trials.
Transitional Care from Paediatric to Adult Services: A Clinical Care Perspective.
Young People and HIV: A Social Support Perspective
Training and presentations: TB and HIV – Yellow Card scheme for reporting adverse drug reactions – feedback from UNGASS, New York and Resistance Workshop, Sitges.
Company meeting: Theratechnologie
Training and presentations: Interpreting risk and confidence in study results – D:A:D study: abacavir, ddI and risk of heart attack – conference feedback from CROI 2008.
Company meeting: GlaxoSmithKline – abacavir and data on risk of heart attack, drugs in development.
Community consultation: BHIVA draft treatment guidelines.